SCHEMBL1703490

SCHEMBL1703490

Cc1cc(C)cc(NC(=O)Nc2ccc(-c3ccnc(Cl)c3C#N)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 7/20 0.57
CSF1R P07333 5/20 0.57
BLK P51451 3/20 0.57
KDR P35968 15/20 0.53
FLT1 P17948 5/20 0.46
FLT3 P36888 5/20 0.46
RPS6KB1 P23443 3/20 0.46
FLT4 P35916 3/20 0.46
AURKA O14965 2/20 0.46
ROCK2 O75116 2/20 0.46
FGFR1 P11362 2/20 0.46
RPS6KA3 P51812 2/20 0.46
ROCK1 Q13464 2/20 0.46
AURKB Q96GD4 2/20 0.46
PLK3 Q9H4B4 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
PDGFRA P16234 4/20 0.46
MET P08581 3/20 0.45
CYP3A4 P08684 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703595 0.90 CYP3A4 (0.58) KITCSF1RBLKKDRFLT1
SCHEMBL1703220 0.86 KDR (0.53) KITCSF1RBLKKDRFLT1
SCHEMBL1703172 0.85 KDR (0.56) KITCSF1RBLKKDRFLT1
SCHEMBL1702911 0.84 KDR (0.60) KITCSF1RBLKKDRFLT1
SCHEMBL3442461 0.83 CYP3A4 (0.60) KITCSF1RBLKKDRFLT1
SCHEMBL1703153 0.82 KDR (0.57) KITCSF1RBLKKDRFLT1
SCHEMBL1704022 0.82 KDR (0.53) KITCSF1RBLKKDRFLT1
SCHEMBL3443154 0.81 CYP3A4 (0.58) KITCSF1RBLKKDRFLT1
SCHEMBL1702802 0.81 KDR (0.57) KITKDRMEN1KMT2APDGFRA
SCHEMBL1703125 0.79 KDR (0.60) KITCSF1RBLKKDRFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807424-B1 NOVEL KINASE INHIBITORS ABBOTT LAB (US) 2012-04-18 EP disclosed
US-7812166-B2 Kinase inhibitors ABBOTT LABORATORIES (US) 2010-10-12 US disclosed
US-20060178378-A1 Novel kinase inhibitors ABBVIE INC. 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178378-A1 Novel kinase inhibitors ABL1, MAP3K19, MAP3K20 KIT 426/4885CSF1R 1265/4885BLK 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.